Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27007129 | 0.92 | KDM4E (0.67) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL10937726 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL1847535 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| Hexamethylenebisacetamide SCHEMBL61980 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL14739904 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL14739632 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL1900654 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL14740132 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL14740196 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL6516953 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1APAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637556-B2 | Linked Myc-max small molecule inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-01-19 | — | — | US | disclosed |
| WO-2010083404-A2 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | MYC, MAX, MYCBP | KDM4E 2681/4885MAPK1 1364/4885HIF1A 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.